Phenomix Sciences
Menlo Park, US · Founded 2020 · Delaware corporation · 3 known investors
Find your way into Phenomix Sciences
65 people in our graph share verified history with the Phenomix Sciences team — schools, employers, funds. One of them is your warm intro.
Rob Purintonunlockedknows Andres Acosta · together at University of Florida (overlapped)
×4knows the team · via Universidad San Francisco de Quito
×7knows the team · via University of Florida
Phenomix Sciences applies data analytics and patient data to enable precision obesity medicine, aiming to guide treatment decisions for anti-obesity medications such as GLP-1s and reduce care costs. Its platform-based approach targets the healthcare market for obesity treatment.
Founders & leadership
Phenomix Sciences was founded in 2020 by Andres Acosta.
AA
Andres AcostainCo-FounderDr. Acosta holds an MD from Universidad San Francisco De Quito and a PhD from the University of Florida, and is board certified in Internal Medicine, Gastroenterology and Hepatology, and Obesity Medicine. He is an Associate Professor of Medicine and Consultant in Gastroenterology and Hepatology at Mayo Clinic, where he directs the Precision Medicine for Obesity Program, and co-founded Phenomix Sciences to develop precision medicine diagnostics for obesity treatment.
MB
Mark BengallExecutive
MB
Mark BagnallinChief Executive Officer
WR
William Ross HigginsExecutive
KR
Karl RonnNamed on SEC filing
MC
Michael CamilleriNamed on SEC filing
Board
LC
Lawrence CohenBoard director
SM
Sean McCauleyBoard director
PO
Paul OwenBoard director
Investors · 3
Also in the syndicate · 2
DexCom, Inc.Labcorp
Reported raises · per SEC filings
Form D private placements$9.7M disclosed across 4 rounds · 2018–2025
▶$2.5MraisedDec 2025 · 4 investors · Other Health CareRule 506(b)
▶$2.5MraisedDec 2025 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence CohenDirector
- Andres AcostaDirector
- Mark BengallExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $2.5M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMay 2024 · 4 investors · Other Health CareRule 506(b)
▶$5MraisedMay 2024 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Andres AcostaDirector
- Michael CamilleriDirector
- Mark BengallExecutive Officer, Director
- Karl RonnDirector
- Lawrence CohenDirector
- Amount sold
- $5M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1MraisedFeb 2023 · 3 investors · Other Health CareRule 506(b)
▶$1MraisedFeb 2023 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Karl RonnDirector
- Michael CamilleriDirector
- Lawrence K CohenDirector
- Mark BagnallExecutive Officer, Director
- Andres AcostaDirector
- Offering amount
- $5M
- Amount sold
- $1M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.1MraisedJan 2020 · 14 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJan 2020 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andres AcostaExecutive Officer, Director, Promoter
- William Ross HigginsExecutive Officer, Promoter
- Paul OwenDirector, Promoter
- Michael CamilleriDirector, Promoter
- Sean McCauleyDirector, Promoter
- Offering amount
- $2M
- Amount sold
- $1.1M
- Minimum investment
- $5K
- Proceeds to insiders
- $170K
- First sale
- May 2018
- Incorporated
- Limited Liability Company, Minnesota, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapGenomind15 shared keywordsGenMedPro is a genetics-based medication management platform that analyzes 26 genes to identify drug-drug and gene-drug interactions across a patient's entire medication regimen. The platform serves healthcare providers and care teams to reduce prescribing errors, prevent adverse events, and optimize medication safety for complex polypharmacy cases.
NeoGenomics14 shared keywordsNeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.
Logomix12 shared keywordsGenome engineering-based drug discovery and biomanufacturing R&D support.
Phenomic AI11 shared keywordsPhenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.
Phenomics Health10 shared keywordsPhenomics Health builds a medication-response intelligence platform that combines high-complexity clinical laboratory testing, pharmacogenomics, pharmacometabolomics, and AI-enabled analytics to support precision prescribing and medication decisions. It serves clinicians, payors, providers, and life-sciences partners in the precision-medicine space.
Companies competing with Phenomix Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Phenomix Sciences do?
- Phenomix Sciences applies data analytics and patient data to enable precision obesity medicine, aiming to guide treatment decisions for anti-obesity medications such as GLP-1s and reduce care costs. Its platform-based approach targets the healthcare market for obesity treatment.
- Who founded Phenomix Sciences?
- Phenomix Sciences was founded by Andres Acosta in 2020.
- Who are Phenomix Sciences's investors?
- Phenomix Sciences's investors include Health2047.
- How much funding has Phenomix Sciences raised?
- Phenomix Sciences has disclosed $9.7M raised across 4 rounds.
- Where is Phenomix Sciences headquartered?
- Phenomix Sciences is headquartered in Menlo Park, US.